Indication
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
1 clinical trial
2 products
Product
AficamtenClinical trial
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic CardiomyopathyStatus: Recruiting, Estimated PCD: 2026-06-01
Product
Placebo